Cempra’s solithromycin receives FDA fast track designation to treat CABP

Clinical-stage pharmaceutical firm Cempra has obtained fast track designation from the US Food and Drug Administration (FDA) for solithromycin intravenous (IV) and capsules to treat community acquired bacterial pneumonia (CABP).
Source: Pharmaceutical Technology - Category: Pharmaceuticals Source Type: news